{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:30:03Z","timestamp":1791847803982,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaad.2022.02.036","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:03:51Z","timestamp":1646078631000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study"],"prefix":"10.1016","volume":"87","author":[{"given":"Adele","family":"Salemme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Scarabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Papini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna Rita","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feliciana","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Lechiancole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bellei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Provini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Sordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Mazzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.02.036_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: from the clinic to the bench","volume":"30","author":"Di Zenzo","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2022.02.036_bib2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2022.02.036_bib3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/1523-1747.ep12382738","article-title":"Development of an ELISA to detect anti\u2013BP180 autoantibodies in bullous pemphigoid and herpes gestationis","volume":"102","author":"Giudice","year":"1994","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.02.036_bib4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1046\/j.1523-1747.2000.00893.x","article-title":"IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH\u2013terminus of BP230","volume":"114","author":"Skaria","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.02.036_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1034\/j.1600-0625.2001.100405.x","article-title":"Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule","volume":"10","author":"Hamada","year":"2001","journal-title":"Exp Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2022.02.036_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.jaad.2022.02.036_bib7","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1111\/jdv.14965","article-title":"Commentary on \u2018changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors\u2019","volume":"32","author":"Fania","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2022.02.036_bib8","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1111\/jdv.14957","article-title":"Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors","volume":"32","author":"Gravani","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2022.02.036_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1684\/ejd.2018.3243","article-title":"Comorbidities of bullous pemphigoid in a Finnish cohort","volume":"28","author":"Pankakoski","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.02.036_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: A case-noncase study in the French pharmacovigilance database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.02.036_bib11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.02.036_bib12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.02.036_bib13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.02.036_bib14","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.02.036_bib15","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.02.036_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA- DQB1\u221703:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","article-title":"Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"78","author":"Fania","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.02.036_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1684\/ejd.2018.3371","article-title":"Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?","volume":"28","author":"Patsatsi","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2022.02.036_bib19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3389\/fimmu.2019.01224","article-title":"Preferential reactivity of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180","volume":"10","author":"Mai","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2022.02.036_bib20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2022.02.036_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2022.02.036_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J Dermatol Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2022.02.036_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid","volume":"49","author":"Ishiura","year":"2008","journal-title":"J Dermatol Sci"},{"issue":"4","key":"10.1016\/j.jaad.2022.02.036_bib25","article-title":"Autoantibody profile of a cohort of 54 Italian patients with linear IgA bullous dermatosis: LAD-1 denoted as a major auto-antigen of the lamina lucida subtype","volume":"100","author":"Cozzani","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2022.02.036_bib26","series-title":"Rapporto anno 2017. Volume 30 Collana Rapporti ARNO. Ed. Cineca, Societ\u00e0 Italiana di Diabetologia, Diabete Ricerca","year":"2017"},{"issue":"9","key":"10.1016\/j.jaad.2022.02.036_bib27","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","article-title":"Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dypeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garcia","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.jaad.2022.02.036_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl- peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.02.036_bib30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipepridyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in\u00a0vivo","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","article-title":"Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease","volume":"2","author":"Remm","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"10.1016\/j.jaad.2022.02.036_bib32","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.celrep.2018.07.093","article-title":"Autoreactive IgG and IgA B cells evolve through distinct subclass switch pathways in the autoimmune disease pemphigus vulgaris","volume":"24","author":"Ellebrecht","year":"2018","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.jaad.2022.02.036_bib33","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1365-2133.2004.06245.x","article-title":"Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients","volume":"151","author":"Mariotti","year":"2004","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.02.036_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archdermatol.2011.21","article-title":"Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid","volume":"147","author":"Roussel","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.02.036_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00403-016-1631-1","article-title":"Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience","volume":"308","author":"Keller","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.jaad.2022.02.036_bib37","first-page":"272","article-title":"Anti-BP180 and anti-BP230 enzyme\u2013linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study","volume":"39","author":"Chanprapaph","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2022.02.036_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4103\/idoj.IDOJ_813_20","article-title":"A cross-sectional study to correlate disease severity in bullous pemphigoid patients with serum levels of autoantibodies against BP180 and BP230","volume":"12","author":"Muhammed","year":"2021","journal-title":"Indian Dermatol Online J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:04:34Z","timestamp":1759273474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222003504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0190962222003504"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.02.036","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.02.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}